Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrapleural sintilimab for malignant pleural effusion in advanced non-small cell lung cancer
ChiCTR2400087743Phase 4Completed
- Sponsor
- General Hospital of Eastern Military Command
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sintilimab in non-small cell lung cancer (NSCLC), sponsored by General Hospital of Eastern Military Command. Primary endpoint: Rate of pleural atresia at Week 5. Started Aug 2024; status: completed.
02
Drugs
sintilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400087743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087743.